profit from every $100 of sales.
$0$100
Bio-Rad Laboratories
$389.98+2.76% today
+25.5% in 1 year
1-year low $255.541-year high $389.98
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $13.80 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bio-Rad Laboratories sold, what it kept, and what it did with the cash.
Sales went from $2.80 billion in 2022 to $2.58 billion in 2025, with $760 million of profit last year.
SalesProfit
Bio-Rad Laboratories handed back 79% of the cash it generated last year.
Buybacks $296M
Free cash flow 2025$375M
Bought back its own shares$296M
Paid as dividends–
Cash vs. debt$530M vs. $1.4B
AI analysis
An AI analyst reads Bio-Rad Laboratories's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,546 | 2,923 | 2,802 | 2,671 | 2,567 | 2,583 | |
| 1,438 | 1,638 | 1,567 | 1,427 | 1,379 | 1,340 | |
| 421 | 500 | 475 | 338 | 269 | 219 | |
| 5,078 | 5,588 | -4,529 | -655 | -2,142 | 1,210 | |
| 3,814 | 4,254 | -3,628 | -637 | -1,844 | 760 | |
| 126.47 | 140.83 | -121.79 | -21.82 | -65.36 | 27.85 | |
| 56.5% | 56.1% | 55.9% | 53.4% | 53.7% | 51.9% | |
| 16.6% | 17.1% | 17.0% | 12.6% | 10.5% | 8.5% | |
| 149.8% | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 12,973 | 17,799 | 13,502 | 12,299 | 9,364 | 10,577 |
| Cash | 662 | 471 | 434 | 404 | 488 | 530 |
| Total debt | 224 | 223 | 1,388 | 1,406 | 1,375 | 1,386 |
| Total liabilities | 3,093 | 4,114 | 3,886 | 3,558 | 2,795 | 3,123 |
| 9,890 | 13,685 | 9,615 | 8,741 | 6,569 | 7,454 | |
| 30 | 30 | 30 | 29 | 28 | 27 | |
| 38.6% | 31.0% | -33.5% | -6.2% | -22.8% | 9.3% | |
| 38.6% | 31.1% | -37.7% | -7.3% | -28.1% | 10.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 585 | 669 | 194 | 375 | 455 | 532 | |
| 109 | 134 | 114 | 157 | 189 | 158 | |
| 476 | 536 | 80 | 218 | 266 | 375 | |
| Dividends paid | – | – | – | – | – | – |
| 100 | 50 | 216 | 429 | 204 | 296 | |
| 42 | 51 | 61 | 61 | 62 | 58 |
Valuation
- 13.8×
- –
- –
- –
- 4.1×
- 28.0×
- 9.4×
- 3.6%
- 7.2%
- –
Profitability
- 51.9%
- 8.5%
- 29.4%
- –
- –
- 0.0%
- –
- –
- –
- –
Growth
- +0.3%
- −26.1%
- –
- –
- +0.0%
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 47%of 884
Top 19%of 601
Bottom 18%of 886
Top 31%of 987
News
Belite Bio Non-GAAP EPS of -$0.60 beats by $0.17Seeking Alpha · Nov 12, 2026MaxCyte falls after $151.8M deal to buy Akron Bio for cash and stockSeeking Alpha · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Bio-Rad Laboratories
Is Bio-Rad Laboratories a good stock to buy?
A strong, very profitable business, and the price looks low. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bio-Rad Laboratories AI analysis
Does Bio-Rad Laboratories pay a dividend?
No. Bio-Rad Laboratories does not pay a dividend at the moment; in 2025 it returned $296 million to shareholders by buying back its own shares.
Is Bio-Rad Laboratories stock halal?
Yes. Bio-Rad Laboratories passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Bio-Rad Laboratories stock done over the past year?
Up 25.5% over the past twelve months, to $389.98. It traded between $255.54 and $389.98, close to its high.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.